AR and neoplasm: Hormone therapy is the current primary treatment for metastatic prostate carcinoma, which implies the lack of circulating testosterone to activate the androgen receptor (AR) in tumor cells, and it may be accomplished by a reduction in testosterone production or by AR blockade (9).